Ever stared at a table of regression coefficients & wondered what you're doing with your life? Very excited to share this gentle introduction to another way of making sense of statistical models (w @vincentab.bsky.social) Preprint: doi.org/10.31234/osf... Website: j-rohrer.github.io/marginal-psy...

I think it's unfortunate when a result publication omits crucial methods. The authors report a risk ratio, from the publication alone it's completely unclear how anything is calculated. They cite their SAP in which they state that they'll report odds ratios and use step-wise variable selection?!

Honestly, some choices I don't quite understand (judging by the abstract only). If the goal is really to compare mini vs normal IUD, then why 4:1 randomization ratio that'll wreck your power? Also a bit strange to not report pearl-index in this study / other studies of non-mini IUD for comparison?

@f2harrell.bsky.social I think the figures in one of your book chapters are broken. At least for me on two devices and two different browsers. hbiostat.org/rmsc/markov

Another @posit.co Positron blog post! To make it easier to work with some huge data in one of my projects, I've loaded it into @duckdb.org. The Connections Pane makes it really easy and convenient to connect to and explore databases with #rstats. Here's how: www.andrewheiss.com/blog/2025/07...

Anyone got any reading tips for blogs or papers on a) generalizability theory with brms b) G theory + IRT (I have Choi's 2017 dissertation)?

Starting to look like I might not be able to work at Harvard anymore due to recent funding cuts. If you know of any open statistical consulting positions that support remote work or are NYC-based, please reach out! 😅

I just published a new #Rstats notebook to celebrate the release of {marginaleffects} 📦 0.26.0: Survival Analysis in R Please send me feedback, and don't forget to update the pkg for important bug fixes. Thanks to Robin Denz for his amazing work on this! marginaleffects.com/bonus/surviv...

📰 New Article: Effects of Janus kinase inhibitors in adults admitted to hospital with #COVID19: a systematic review and IPD meta-analysis of randomised clinical trials Findings suggested that JAK inhibitors reduced mortality across all levels of respiratory support 🔗 tinyurl.com/2hprv99v

🚨Save the date! March 26th, Prof. @stephensenn.bsky.social will travel to #Basel and give a presentation on methodology and statistics in #RCTs. He will share his insights on why we randomize trials, the value of balance, whether trials should be representative, and much more.

"A Latent Causal Inference Framework for Ordinal Variables" Paper: arxiv.org/abs/2502.10276 #rstats Code: github.com/martinascaud... #stats

New WP with @vincentab.bsky.social @ryancbriggs.net. We use LLMs and RAs to track publication trends in polisci. Here’s how subfields have changed in AJPS and JOP osf.io/v7fe8

The Lancet Infectious Diseases is on Bluesky now! Have we missed anything? Quiet time of the year, isn't it... 👉 Follow us for the newest research and commentary in infectious diseases! #IDSky

An issue that often comes up is how to set a “non-inferiority margin” in a non-inferiority trial and how to ensure it is appropriate 1/8 #MethodologyMonday #109

Please stop telling me about risk factors. 🙏😖 (ICYMI) statsepi.substack.com/p/sorry-what...

"Bluesky moderation lists create echo chambers." A short thread about decentralized moderation on Bluesky and why it changes everything.* 🧵 *Based on nearly a thousand hours spent exploring the platform's code.

6/ The second fantastic post: "Syllabi | Improving Clinical Trial Design" by @scientificdiscovery.dev A list of fantastic materials around clinical trials, from introductory to advanced. t.co/gDTEUOHkkB

1/ Excited to share thoughts on two excellent blog posts about clinical trials! First up: "The Case for Clinical Trial Abundance" by @ruxandrabio.bsky.social and Willy Chertman . They argue we need more clinical trials & that bureaucracy hampers faster progress. A sentiment I fully share!

Emma Hodcroft is named a person to watch in shaping science in 2025 by the renowned journal Nature!🏅 Hodcroft, group leader at Swiss TPH & assistant professor @unibas.ch, is recognised for advancing #OpenScience by co-creating the open-source Pathoplexus database for sharing viral pathogen genomes.

I quickly simulated this for a continuous outcome, because I lack the theoretical understanding. I think you are right, but I'm slightly confused as to why the increased precision doesn't decrease the type I error rate in this case.

Despite a massive head start, BlueSky has now overtaken Threads in the US 👇

1/3) An issue is that since the FDA commonly uses a two sided significance level for conventional trials but would never register a drug unless superiority were shown, operationally, the test is 2.5% one-sided. For consistency Schuirmann’s test should be two tests at the 2.5% level requiring 95% CIs

Did you just present new #TrialsMethodology guidance at #ICTMC2024? Have a look at our new database and check whether it is already in it. If not, send it along! lights.science

"Reading and conducting instrumental variable studies: guide, glossary, and checklist" - nice new paper in the @bmj.com from @tfeend.bsky.social and colleagues! #EpiSky #StatsSky www.bmj.com/content/387/...

Our World in Data now has an account on Bluesky! Follow us here: @ourworldindata.bsky.social

New blog post (matthewbjane.github.io/blog-posts/b...) AND I have just uploaded a page on my website that hosts a living meta-analysis for the effects of Social Media and Mental Health (matthewbjane.github.io/social_media...). The effects are re-calculated with a new and improved model. #stats